SLC5A2 and chronic kidney disease: Furthermore, in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, SGLT2 inhibitors were shown to offer renal protection not only in patients with DM but also in non-DM patients with proteinuria, suggesting that SGLT2 inhibitors confer renal protection beyond sugar-lowering effects [20].